Deep-brain recordings show Mounjaro and Zepbound briefly shut down craving circuits linked to food noise in a patient with severe obesity.
Deep-brain recordings showed that Mounjaro and Zepbound briefly shut down the craving circuits linked to food noise in a patient with severe obesity. Her obsessive thoughts about food disappeared as the medication quiete
A recent study utilized deep-brain recording techniques to investigate the neural mechanisms underlying appetite suppression associated with GLP-1 receptor agonists. The research focused on a patient with severe obesity who experienced significant changes in food-related behavior following treatment with Mounjaro and Zepbound.
The primary objective was to determine whether these medications directly influence brain activity related to food cravings. By employing deep-brain recordings, researchers aimed to observe real-time neural responses during periods of medication administration and withdrawal.
Findings indicated that both Mounjaro and Zepbound temporarily suppressed craving circuits associated with food noise in the patient's brain. Specifically, obsessive thoughts regarding food ceased as the medications quieted activity within the nucleus accumbens, a region identified as the brain's reward hub. This suggests a direct modulation of neural pathways involved in reward processing.
However, these effects were observed to be brief and transient. The study did not provide long-term data on sustained craving suppression or metabolic outcomes beyond the immediate recording period. Additionally, the findings are limited to a single patient case, which restricts generalizability across broader populations.
These results highlight potential neural mechanisms for appetite regulation but emphasize the need for further investigation with larger cohorts. The research underscores the importance of understanding brain activity patterns when evaluating therapeutic efficacy in metabolic conditions.